Intralesional MMR Vaccine Outperforms Vitamin D in Wart Treatment, Study Finds

For this purpose, the researchers enrolled 112 participants with multiple warts, dividing them into two groups. Group I (56 participants) received 0.3 mL of intralesional MMR vaccine, while Group II (56 participants) received 0.3 mL of intralesional vitamin D3. Injections were given every two weeks into the most noticeable wart, with up to five sessions. The participants were followed up for six months after their final treatment.

Key findings were as follows:

• The MMR group showed a significantly higher complete response rate (80.4%) than the vitamin D group (66.1%).
• Both groups received an average of four treatment sessions, with no significant difference.
• The MMR group experienced significantly higher rates of mild pain (96.4%) and injection site itching (12.5%) than the vitamin D group.
• After six months of follow-up, the recurrence rates were similar in both groups, with 3 cases (5.4%) in the vitamin D group and 2 cases (3.6%) in the MMR group.

The researchers concluded that intralesional MMR demonstrated greater efficacy than vitamin D in treating warts, though with a higher incidence of tolerable side effects. Both treatments were safe, effective, and cost-efficient for wart therapy, offering low recurrence rates. As such, immunotherapy, including intralesional MMR and vitamin D, may be a suitable option for managing multiple, disseminated, and recalcitrant warts.

"The study, however, acknowledges certain limitations, including the lack of assessment of viral types and serum cytokine levels before and after treatment. Further studies are needed to explore the effect of these injections on cytokine serum levels," the researchers wrote.

Reference:

Sallam M, Awad A, Hamdy S, State A. Intralesional measles, mumps, and rubella vaccine versus vitamin D for treatment of warts: A randomised clinical trial. Indian J Dermatol Venereol Leprol. doi: 10.25259/IJDVL_1669_2024